| VC-Backed Life Sciences Companies Get Fresh Cash The Burrill Report submits: By Marie DaghlianMay ended with a slew of venture-backed companies receiving fresh capital to move development of their products. Medtronic (MDT) made the biggest investment, putting $70 million into Israeli medical device company BioControl Medical. It was an unusual type of investment because the company’s previous investors opted for a direct investment with an option to acquire the company rather than a typical financing round.Complete Story » seekingalpha.com |
Adolor's Pain Continues as Osteoarthritis Drugs Fail in Trial EP Vantage submits:Sometimes it does not just rain it pours. For Adolor (ADLR), this week has been a very stormy affair. First it announced Thursday that both its novel opioid drugs, ADL5859 and ADL5747, failed in a phase IIa osteoarthritis (OA) trial. Friday, this failure was further compounded by the fact that Pfizer’s (PFE) own OA drug tanezumab, a monoclonal antibody, had succeeded in phase III trials. Shares in Adolor reacted to the poor trial outcomes of ADL5859 and ADL5747 by dipping 15% Friday to $1.28, a five-year low. This leaves the company with a market value of $59.3m, below current cash levels of about $73m, and question marks hanging overhead, about whether Adolor could now be a suitable takeout target for a cash-hungry company.Complete Story » seekingalpha.com |
Good News for Generex: Positive Data on Oral Insulin Coming in September R.J Steffens submits:"I poke my fingers to check my sugar. I have to take shots before I eat. I’m tired of all this. I wish it was easier. I can’t go to my friends’ houses. They don’t know what to do". ~ Josh from An Anthology of Poems by Kids with DiabetesWhile subcutaneous insulin is effective in controlling blood glucose and HbAIc concentrations, the required injections can be a burden for patients, which can impact compliance. Patients and physicians hesitate initiating insulin therapy for several reasons, such as concern that injections are painful, difficult to administer, inconvenient, and the overall perception that initiating insulin treatment signifies a dramatic worsening of the disease. These inherent limitations are among other possible reasons why diabetics often have poorly controlled HbA1c levels while on conventional insulin therapies.Complete Story » seekingalpha.com |
Peregrine Pharmaceuticals CEO Discusses F1Q2011 Results - Earnings Call Transcript Peregrine Pharmaceuticals, Inc. (PPHM)F1Q2011 Earnings Call TranscriptSeptember 9, 2010 4:30 pm ETComplete Story » seekingalpha.com |
Biogen Idec: Earnings Preview Zacks.com submits: Biogen Idec Inc. (BIIB) is slated to announce its third quarter results on October 26. The Zacks Consensus Estimate is $1.20, well above the year-earlier earnings of $1.09. Second Quarter HighlightsComplete Story » seekingalpha.com |